Soliris REMS Should Be Modified, Not Eliminated, FDA Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Alexion’s risk management program could benefit from easing current requirement for MedGuide distribution with every infusion and streamlining surveys of prescribers’ knowledge about meningococcal risks.